Research Topics
| Scott R EvansSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
A comparison of goodness of fit tests for the logistic GEE modelScott Evans
Department of Biostatistics, Center for Biostatistics in AIDS Research, Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
Stat Med 24:1245-61. 2005..We evaluate the performance of each of the statistics with respect to type I error rates and power in a simulation study. Guidance is provided regarding appropriate use of the statistics under various scenarios...
Peripheral neuropathy in HIV: prevalence and risk factorsScott R Evans
Harvard School of Public Health, 651 Huntington Avenue, Boston, MA 02115, USA
AIDS 25:919-28. 2011....- A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic painScott R Evans
Harvard School of Public Health, Boston, Massachusetts, United States of America
PLoS ONE 2:e551. 2007..To examine the efficacy and safety of Prosaptide (PRO) for the treatment of painful HIV-associated sensory neuropathies (HIV-SN)... - Simplification of the research diagnosis of HIV-associated sensory neuropathyScott R Evans
Harvard School of Public Health, Boston, Massachusetts 02115, USA
HIV Clin Trials 9:434-9. 2008.... - HIV peripheral neuropathy progression: protection with glucose-lowering drugs?Scott R Evans
Center for Biostatistics in AIDS Research, Department of Biostatistics, FXB 513 Harvard School of Public Health, Boston, MA 02115, USA
J Neurovirol 18:428-33. 2012..21, 3.85), p = 0.009) while use of glucose-lowering drugs (non-insulin) was protective (OR = 0.12, 95 % CI = (0.02, 0.83), p = 0.031). Use of glucose-lowering drugs (non-insulin) may prevent progression from APN to SPN... - Memantine for AIDS dementia complex: open-label report of ACTG 301Yu Zhao
Harvard School of Public Health, Boston, Massachusetts, USA
HIV Clin Trials 11:59-67. 2010..To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment... - Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211Tzu Min Yeh
Harvard School of Public Health, Boston, Massachusetts 02115, USA
HIV Clin Trials 11:51-8. 2010..To evaluate the effect of vicriviroc (VCV) on peripheral neuropathy (PN), the most prevalent neurological complication of HIV infection in HIV-1-infected treatment- experienced population... - Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090Scott R Evans
Harvard School of Public Health, Boston, Massachusetts, USA
HIV Clin Trials 8:437-46. 2007..To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment... - Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohortMarlene Smurzynski
Harvard School of Public Health, Department of Biostatistics, Boston, Massachusetts 02115, USA
AIDS 25:357-65. 2011..We assessed the relationship between estimates of antiretroviral therapy penetration into the CNS, using a published ranking system, and neurocognitive status in HIV-positive participants with plasma HIV-1 RNA (vRNA) suppression... - Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087Scott R Evans
Harvard School of Public Health, Boston, MA, USA
HIV Clin Trials 8:45-52. 2007..Triglyceride (TG) levels >400 mg/dL interfere with the accurate determination of low-density lipoproteins (LDL-C) by the Friedewald equation, making it difficult to assess coronary heart disease risk...